Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 HKD | +2.53% |
|
-5.45% | -63.40% |
06-05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
06-05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.40% | 293M | |
+38.36% | 52.73B | |
+36.73% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Presents Results of Phase 1/2 China Trial for Tumor Drug in US Oncology Meeting